AES Clinical Corner: Ganaxolone (Ztalmy®)
This AES Clinical Corner video focuses on Ganaxolone (Ztalmy®), a medication approved by the FDA on March 18, 2022, for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.
Elia Pestana Knight, MD, the lead author of a Lancet Neurology study supporting the FDA approval and member of the AES Treatments Committee; Barry Gidal, PharmD, FAES; and John Stern, MD, FAES, discuss study details and considerations for clinicians. Dosage and administration information for ganaxolone oral suspension and other important details can be found in the FDA Prescribing Information.
Panelists: Elia Pestana Knight, MD; Barry Gidal, PharmD, FAES; and John Stern, MD, FAES
.png?sfvrsn=3c21b78a_1)
Click here to view the Drug News and FDA Alerts webpage.
AES Clinical Corner: Paxlovid
On December 22, 2021, the FDA issued an Emergency Use Authorization for Paxlovid™, a new COVID-19 oral antiviral medication. In addition to a summary of the key information from the FDA and other sources about related drug interactions and important considerations for providers with patients on antiseizure medications, the AES Treatments Committee discussed the issues in this convenient fifteen-minute AES Clinical Corner video.
Panelists: Barry Gidal, PharmD, FAES; Jon Cokley, PharmD; and David Vossler, MD, FAES
Click here for more information on Paxlovid™ and considerations for providers with patients on ASMs.